ClinicalTrials.Veeva

Menu

Immunocompetent Versus Immunocompromised Tuberculosis (TB) Patients

S

Sohag University

Status

Not yet enrolling

Conditions

Tuberculosis

Treatments

Diagnostic Test: zeihl - Nelsen stain
Diagnostic Test: Molecular detection of antibiotic resistance
Diagnostic Test: P24 antigens and antibody
Diagnostic Test: culture on Lowenstein jensen media

Study type

Observational

Funder types

Other

Identifiers

NCT06709157
Soh-Med-24-08--05PD

Details and patient eligibility

About

Tuberculosis (TB) is caused by Mycobacterium tuberculosis and is one of the top 10 causes of mortality worldwide. It is estimated that in 2017, 10 million people were infected with TB, and 1.6 million died from the disease, including 0.3 million people with human immunodeficiency virus (HIV) infection . TB remains the primary killer of HIV-positive individuals. TB incidence is falling at about 2% per year . Airborne transmission of M. tuberculosis typically causes TB infection in both immunocompetent and immunocompromised hosts and the disease is symptomatic and contagious .

Full description

TB and HIV infections are strictly linked together. TB is the most common opportunistic infection and causes high morbidity rate among people living with HIV. Because of the decrease in cell-mediated immunity, HIV alters the pathogenesis of TB, thereby expressively increasing the risk of TB in HIV-positive patients and eventually leading to more severe complications and forms of TB.

Enrollment

200 estimated patients

Sex

All

Ages

16 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with chronic chest disease

Exclusion criteria

  • Patients with other respiratory or infectious diseases.

Trial contacts and locations

1

Loading...

Central trial contact

Mona Lecturer; Noha S Shafik, Lecturer

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems